Article type
Year
Abstract
Background: Hypertension is the most important risk factor of cardiovascular disease. The number of adults with hypertension in 2025 was predicted to 1.56 billion. There were 200 million hypertensive patients in China.
Objectives: To select essential antihypertensive medicine based on burden of disease for township health center located in the Eastern, Central and Western China.
Methods: Evidence-based approaches were applied to evaluate and recommend essential medicine using the criteria, methods and workflow addressed in our previous study.
Results: Five clinical guidelines on hypertension were included, two of which were evidence based ones. In total, there were nine classes and 70 kinds of antihypertensive medicines listed in the guidelines. Nifedipine, Verapamil and Enalapril were strongly recommended as essential medicines and Hydrochlorothiazide, Indapamide, Spironolactone, Propranolol, Metoprolol and Amlodipine were weakly recommended, while Furosemide and Timolol were not recommended, according to WHO EML, Chinese EML, Chinese National Formulary, the clinical guidelines and the quantity and quality of evidence included in the guidelines. Nine recommended medicines have been marketed in China in the according dosage forms and specifications. The prices of Metoprolol, Amlodipine and Enalapril were higher than other six medicines. In total, the prices of the recommended antihypertensive medicines were affordable. Domestic researches showed that Nifedipine, Verapamil and Enalapril, which were recommended strongly, were safe, effective, economical and applicable.
Conclusions: Nifedipine, Verapamil and Enalapril are strongly recommended as antihypertensive medicines, while Hydrochlorothiazide, Indapamide, Spironolactone, Propranolol, Metoprolol and Amlodipine are weakly recommended. There is less high-quality evidence as of antihypertensive medicines produced in China, especially long-term safety and economy evidence. It is suggested to carry out the safety, effectiveness and economy research for the six weakly-recommended antihypertensive medicines to produce local evidence with high quality. This study is funded by the Chinese National Science & Technology Program 11th Five-Year Plan (2008BAI65B22).
Objectives: To select essential antihypertensive medicine based on burden of disease for township health center located in the Eastern, Central and Western China.
Methods: Evidence-based approaches were applied to evaluate and recommend essential medicine using the criteria, methods and workflow addressed in our previous study.
Results: Five clinical guidelines on hypertension were included, two of which were evidence based ones. In total, there were nine classes and 70 kinds of antihypertensive medicines listed in the guidelines. Nifedipine, Verapamil and Enalapril were strongly recommended as essential medicines and Hydrochlorothiazide, Indapamide, Spironolactone, Propranolol, Metoprolol and Amlodipine were weakly recommended, while Furosemide and Timolol were not recommended, according to WHO EML, Chinese EML, Chinese National Formulary, the clinical guidelines and the quantity and quality of evidence included in the guidelines. Nine recommended medicines have been marketed in China in the according dosage forms and specifications. The prices of Metoprolol, Amlodipine and Enalapril were higher than other six medicines. In total, the prices of the recommended antihypertensive medicines were affordable. Domestic researches showed that Nifedipine, Verapamil and Enalapril, which were recommended strongly, were safe, effective, economical and applicable.
Conclusions: Nifedipine, Verapamil and Enalapril are strongly recommended as antihypertensive medicines, while Hydrochlorothiazide, Indapamide, Spironolactone, Propranolol, Metoprolol and Amlodipine are weakly recommended. There is less high-quality evidence as of antihypertensive medicines produced in China, especially long-term safety and economy evidence. It is suggested to carry out the safety, effectiveness and economy research for the six weakly-recommended antihypertensive medicines to produce local evidence with high quality. This study is funded by the Chinese National Science & Technology Program 11th Five-Year Plan (2008BAI65B22).